Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-611-5 | CAS number: 123-23-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 of the test item in the male rat was determined to be 3257 mg/kg. If the rat were female, the oral LD50 was determined to be 2646 mg/kg. In the sexes combined, the oral LD50 was determined to be 3100 mg/kg.
The acute dermal LD50 of the test item was estimated to be greater than 2000 mg/kg in the rat.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- from 1996-06-04 to 1996-09-19
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- OECD Guidelines for the Testing of Chemicals, Section 4, Health Effects, Subsection 401, February 24, 1987.
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Version / remarks:
- The EEC Guidelines Part B: Methods for the Determination of Toxicity, No. L 383 A/110, B.1, December 29, 1992.
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.1175 (Acute Oral Toxicity)
- Version / remarks:
- Toxic Substances Control Act Test Guidelines, 40 CFR Part 798, Subpart B, Section 798.1175, July 1, 1992.
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Specific details on test material used for the study:
- Lot No.: 0998603612
Purity: 59.6 % - Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD®BR VAF/Plus®
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Portage, Michigan, USA
- Females nulliparous and non-pregnant: yes
- Housing: individually in suspended stainless steel cages
- Weight at study initiation: males: 212 - 242 g; females: 216 - 241 g
- Age at study initiation: young adults
- Fasting period before study: overnight
- Diet: PMI Certified Rodent Chow #5002 (Purina Mills, Inc.) was provided ad libitum to the animals throughout the study (except during fasting).
- Water: Municipal tap water treated by reverse osmosis was available ad libitum throughout the study.
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 16 - 21 °C (60 - 70 °F)
- Humidity (%): 52 - 71
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Single oral dose application. The test item was applied in its initial form.
- Doses:
- 2000, 3500 and 5000 mg/kg
- No. of animals per sex per dose:
- 5 females and 5 males per dose
- Control animals:
- no
- Details on study design:
- Oral application on day 0. Post-dose observational period - 14 days.
- Statistics:
- The LD50 and 95% confidence intervals were calculated separately for males, females and the combined sexes using a computer adaption of the method of Litchfield and Wilcoxon.
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3 256.8 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 2 537.8 - <= 4 179.4
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 2 645.8 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 2 279.5 - <= 3 070.8
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 3 099.8 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 2 707.6 - <= 3 548.9
- Mortality:
- Four males and five females died in both the 3500 and 5000 mg/kg dose groups. All mortality occurred by study day 6.
- Clinical signs:
- other: The most notable clinical abnormalities observed during the study in both the animals that died and those that survived included decreased activity, breathing abnormalities, decreased to no defecation, piloerection, hunched posture, rough haircoat, dehydr
- Gross pathology:
- The most notable gross internal findings were observed in the animals that died and included abnormal contents, discoloration and thickened mucosa in the digestive tract, reddened thymus, abnormal and discolored contents in the trachea, abnormal contents in the urinary bladder, discolored lungs, livers and pancreas and congested meningeal vessels in the brain. No significant gross internal findings were observed at necropsy on study day 14, however single incidences of dilated pelvis of the kidney, gray raised area(s) on the spleen, thickened stomach mucosa and adhesion on the abdominal cavity were noted.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this test, the acute oral LD50 of the test item in the male rat was determined to be 3257 mg/kg. If the rat were female, the oral LD50 was determined to be 2646 mg/kg. In the sexes combined, the oral LD50 was determined to be 3100 mg/kg.
- Executive summary:
The single-dose oral toxicity of Succinic Acid Peroxide was evaluated in Sprague-Dawley rats. An LD50 study was performed in which three groups of five male and five female rats received a single oral administration of the test article at graded dosage levels. Following dosing, the LD50 study rats were observed daily and weighed weekly. A gross necropsy examination was performed on all LD50 study animals at the time of death or scheduled euthanasia (day 14). Mortality occurred during the LD50 study in dose levels 3500 and 5000 mg/kg - 4 males and 5 females died ind each dose group. All mortality occurred by study day 6.
The most notable clinical abnormalities observed during the study in both the animals that died and those that survived included decreased activity, breathing abnormalities, decreased to no defecation, piloerection, hunched posture, rough haircoat, dehydration, dark material around facial area, low food consumption, lacrimation, and feces small in size. Fecal/urine stain and distended abdomen were noted only in the surviving animals. Additional clinical abnormalities noted in the animals that died only included prostration, apparent hypothermia, extremities pale in color, cyanosis, wobbly gait and eyelids partially closed. Salivation was also noted on day 0 only in both the animals that survived and those that died and was probably related to the irritant nature of the test article. Body weight loss was noted in one 2000 mg/kg female during the day 0 to 7 body weight interval. Body weight gain was noted for all other surviving animals during the test period. The most notable gross internal findings were observed in the animals that died and included abnormal contents, discoloration and thickened mucosa in the digestive tract, reddened thymus, abnormal and discolored contents in the trachea, abnormal contents in the urinary bladder, discolored lungs, livers and pancreas and congested meningeal vessels in the brain. No significant gross internal findings were observed at necropsy on study day 14, however single incidences of dilated pelvis of the kidney, gray raised area(s) on the spleen, thickened stomach mucosa and adhesion on the abdominal cavity were noted.
Under the conditions of this test, the acute oral LD50 of Succinic Acid Peroxide in the male rat was determined to be 3257 mg/kg. If the female rat, the dermal LD50 was determined to be 2646 mg/kg. In the sexes combined, the dermal LD50 was determined to be 3100 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 100 mg/kg bw
- Quality of whole database:
- 1 study report, GLP conformity, performed according to OECD, EEC and EPA Guidelines.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- from 1996-06-04 to 1996-09-20
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.1100 (Acute Dermal Toxicity)
- Version / remarks:
- Toxic Substances Control Act Test Guidelines, 40 CFR Part 798, Subpart B, Section 798.1100, July 1, 1992.
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- OECD Guidelines for the Testing of Chemicals, Section 4, Health Effects, Subsection 402, February 24, 1987.
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- The EEC Guidelines Part B: Methods for the Determination of Toxicity, No. L 383 A/121, B.3, December 29, 1992.
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- Lot No.: 0998603612
Purity: 59.6 % - Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD®BR VAF/Plus®
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Portage, Michigan, USA
- Females nulliparous and non-pregnant: yes
- Age at study initiation: young adults
- Weight at study initiation: males: 264 - 351 g; females: 221 - 243 g
- Housing: individually in suspended stainless steel cages
- Diet: PMI Certified Rodent Chow #5002 (Purina Mills, Inc.) was provided ad libitum to the animals throughout the study.
- Water: Municipal tap water treated by reverse osmosis was available ad libitum throughout the study.
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 15 - 20.5 °C (59 - 69 °F)
- Humidity (%): 52 - 80
- Air changes (per hr): 10- 15
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: the dorsal trunk area of the animals, the fur was shaved and the area was clipped
- % coverage: ≥ 10% of the animal's body surface area (BSA)
- Type of wrap: an appropriately sized 4 ply porous gauze dressing, a plastic wrap and an elastic wrap
REMOVAL OF TEST SUBSTANCE
- Washing: Residual test article was removed using gauze moistened with distilled water followed by dry gauze.
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount applied: 4 mL/kg
- Concentration: 2000 mg/kg - Duration of exposure:
- 24 h exposure, 14 days observation after exposure
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 males and 5 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Individual body weights were obtained for the limit test animals prior to dosing on day 0 and on days 7 and 14.
- Necropsy of survivors performed: yes
- Other examinations performed:
= clinical signs: Limit test animals were observed for clinical abnormalities a minimum of two times on study day 0 (postdose) and daily thereafter (days 1-14). A general health/mortality check was performed twice daily.
= dermal observations: Limit test animals were examined for erythema and edema following patch removal on study day 1 and daily thereafter (days 2-14) according to the Macroscopic Dermal Grading System based on Draize. The dermal test sites were reclipped as necessary to allow clear visualization of the skin. - Statistics:
- Data from the limit test were analyzed and an LD50 value estimated as follows:
< 50% Mortality: LD50 was estimated as greater than the administered dose.
= 50% Mortality: LD50 was estimated as equal to the administered dose.
> 50% Mortality: LD50 was estimated as less than the administered dose. - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred during the limit test.
- Clinical signs:
- other: The most notable clinical abnormalities observed during the study included dark material around facial area, and urine stain. Dermal irritation was noted at the site of test article application.
- Gross pathology:
- No significant gross internal findings were observed at necropsy on study day 14.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this test, the acute dermal LD50 of the test item was estimated to be greater than 2000 mg/kg in the rat.
- Executive summary:
The single-dose dermal toxicity of the test item was evaluated on Sprague-Dawley rats. A limit test was performed in which one group of five male and five female rats received a single dermal administration of the test item at a dose of 2000 mg/kg body weight. Following dosing, the rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the time of death or scheduled euthanasia (day 14).
No mortality occurred during the limit test. The most notable clinical abnormalities observed during the study included dark material around facial area, and urine stain. Dermal irritation was noted at the site of test article application. Body weight gain was noted for all animals during the test period. No significant gross internal findings were observed at necropsy on study day 14.
Under the conditions of this test, the acute dermal LD50 of the test item was estimated to be greater than 2000 mg/kg in the rat.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- 1 study report, GLP conformity, performed according to OECD, EEC and EPA Guidelines.
Additional information
Acute oral
The single-dose oral toxicity of Succinic Acid Peroxide was evaluated in Sprague-Dawley rats. An LD50 study was performed in which three groups of five male and five female rats received a single oral administration of the test article at graded dosage levels. Following dosing, the LD50 study rats were observed daily and weighed weekly. A gross necropsy examination was performed on all LD50 study animals at the time of death or scheduled euthanasia (day 14). Mortality occurred during the LD50 study in dose levels 3500 and 5000 mg/kg - 4 males and 5 females died ind each dose group. All mortality occurred by study day 6.
The most notable clinical abnormalities observed during the study in both the animals that died and those that survived included decreased activity, breathing abnormalities, decreased to no defecation, piloerection, hunched posture, rough haircoat, dehydration, dark material around facial area, low food consumption, lacrimation, and feces small in size. Fecal/urine stain and distended abdomen were noted only in the surviving animals. Additional clinical abnormalities noted in the animals that died only included prostration, apparent hypothermia, extremities pale in color, cyanosis, wobbly gait and eyelids partially closed. Salivation was also noted on day 0 only in both the animals that survived and those that died and was probably related to the irritant nature of the test article. Body weight loss was noted in one 2000 mg/kg female during the day 0 to 7 body weight interval. Body weight gain was noted for all other surviving animals during the test period. The most notable gross internal findings were observed in the animals that died and included abnormal contents, discoloration and thickened mucosa in the digestive tract, reddened thymus, abnormal and discolored contents in the trachea, abnormal contents in the urinary bladder, discolored lungs, livers and pancreas and congested meningeal vessels in the brain. No significant gross internal findings were observed at necropsy on study day 14, however single incidences of dilated pelvis of the kidney, gray raised area(s) on the spleen, thickened stomach mucosa and adhesion on the abdominal cavity were noted.
Under the conditions of this test, the acute oral LD50 of Succinic Acid Peroxide in the male rat was determined to be 3257 mg/kg. If the female rat, the dermal LD50 was determined to be 2646 mg/kg. In the sexes combined, the dermal LD50 was determined to be 3100 mg/kg.
Acute dermal
The single-dose dermal toxicity of the test item was evaluated on Sprague-Dawley rats. A limit test was performed in which one group of five male and five female rats received a single dermal administration of the test item at a dose of 2000 mg/kg body weight. Following dosing, the rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the time of death or scheduled euthanasia (day 14).
No mortality occurred during the limit test. The most notable clinical abnormalities observed during the study included dark material around facial area, and urine stain. Dermal irritation was noted at the site of test article application. Body weight gain was noted for all animals during the test period. No significant gross internal findings were observed at necropsy on study day 14.
Under the conditions of this test, the acute dermal LD50 of the test item was estimated to be greater than 2000 mg/kg in the rat.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. The LD50 was greater than 2000 mg/kg bw in both oral and dermal exposure studies. As a result the substance is not considered to be classified for acute oral and dermal toxicity under Regulation (EC) No 1272/2008, as amended for the tenth time in Regulation (EU) No 2017/776.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.